Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector

M. Takahashi, G. Valdes, K. Hiraoka, A. Inagaki, S. Kamijima, E. Micewicz, H. E. Gruber, J. M. Robbins, D. J. Jolly, W. H. McBride, K. S. Iwamoto, Noriyuki Kasahara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a radiosensitizing agent. Efficient transduction by RRV and expression of CD were confirmed in the highly aggressive, radioresistant human glioblastoma cell line U87EGFRvIII and its parental cell line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival assay and in vivo by bioluminescence imaging analysis. These results provide a convincing rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-selective replicative capability of RRV, and incorporation of radiation therapy into future clinical trials evaluating Toca 511 and Toca FC in brain tumor patients.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalCancer Gene Therapy
Volume21
Issue number10
DOIs
StatePublished - Oct 25 2014

Fingerprint

Prodrugs
Flucytosine
Glioma
Fluorouracil
Genetic Therapy
Cytosine Deaminase
Neoplasms
Clinical Trials
Radiation-Sensitizing Agents
Cell Line
Glioblastoma
Brain Neoplasms
Radiotherapy
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. / Takahashi, M.; Valdes, G.; Hiraoka, K.; Inagaki, A.; Kamijima, S.; Micewicz, E.; Gruber, H. E.; Robbins, J. M.; Jolly, D. J.; McBride, W. H.; Iwamoto, K. S.; Kasahara, Noriyuki.

In: Cancer Gene Therapy, Vol. 21, No. 10, 25.10.2014, p. 405-410.

Research output: Contribution to journalArticle

Takahashi, M, Valdes, G, Hiraoka, K, Inagaki, A, Kamijima, S, Micewicz, E, Gruber, HE, Robbins, JM, Jolly, DJ, McBride, WH, Iwamoto, KS & Kasahara, N 2014, 'Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector', Cancer Gene Therapy, vol. 21, no. 10, pp. 405-410. https://doi.org/10.1038/cgt.2014.38
Takahashi, M. ; Valdes, G. ; Hiraoka, K. ; Inagaki, A. ; Kamijima, S. ; Micewicz, E. ; Gruber, H. E. ; Robbins, J. M. ; Jolly, D. J. ; McBride, W. H. ; Iwamoto, K. S. ; Kasahara, Noriyuki. / Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. In: Cancer Gene Therapy. 2014 ; Vol. 21, No. 10. pp. 405-410.
@article{15e86230f4fe41f7adf85b56705cfdb0,
title = "Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector",
abstract = "A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a radiosensitizing agent. Efficient transduction by RRV and expression of CD were confirmed in the highly aggressive, radioresistant human glioblastoma cell line U87EGFRvIII and its parental cell line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival assay and in vivo by bioluminescence imaging analysis. These results provide a convincing rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-selective replicative capability of RRV, and incorporation of radiation therapy into future clinical trials evaluating Toca 511 and Toca FC in brain tumor patients.",
author = "M. Takahashi and G. Valdes and K. Hiraoka and A. Inagaki and S. Kamijima and E. Micewicz and Gruber, {H. E.} and Robbins, {J. M.} and Jolly, {D. J.} and McBride, {W. H.} and Iwamoto, {K. S.} and Noriyuki Kasahara",
year = "2014",
month = "10",
day = "25",
doi = "10.1038/cgt.2014.38",
language = "English (US)",
volume = "21",
pages = "405--410",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector

AU - Takahashi, M.

AU - Valdes, G.

AU - Hiraoka, K.

AU - Inagaki, A.

AU - Kamijima, S.

AU - Micewicz, E.

AU - Gruber, H. E.

AU - Robbins, J. M.

AU - Jolly, D. J.

AU - McBride, W. H.

AU - Iwamoto, K. S.

AU - Kasahara, Noriyuki

PY - 2014/10/25

Y1 - 2014/10/25

N2 - A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a radiosensitizing agent. Efficient transduction by RRV and expression of CD were confirmed in the highly aggressive, radioresistant human glioblastoma cell line U87EGFRvIII and its parental cell line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival assay and in vivo by bioluminescence imaging analysis. These results provide a convincing rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-selective replicative capability of RRV, and incorporation of radiation therapy into future clinical trials evaluating Toca 511 and Toca FC in brain tumor patients.

AB - A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a radiosensitizing agent. Efficient transduction by RRV and expression of CD were confirmed in the highly aggressive, radioresistant human glioblastoma cell line U87EGFRvIII and its parental cell line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival assay and in vivo by bioluminescence imaging analysis. These results provide a convincing rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-selective replicative capability of RRV, and incorporation of radiation therapy into future clinical trials evaluating Toca 511 and Toca FC in brain tumor patients.

UR - http://www.scopus.com/inward/record.url?scp=84908219652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908219652&partnerID=8YFLogxK

U2 - 10.1038/cgt.2014.38

DO - 10.1038/cgt.2014.38

M3 - Article

C2 - 25301172

AN - SCOPUS:84908219652

VL - 21

SP - 405

EP - 410

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 10

ER -